Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Concept / HPPD
Concept

HPPD

HPPD (hallucinogen persisting perception disorder) is a condition where visual disturbances from a past psychedelic experience — trails, afterimages, halos, geometric patterns, 'visual snow' — keep recurring while completely sober, sometimes long after use. It is recognized in the DSM-5. Genuine chronic HPPD is rare, it is not physically dangerous, but it can be distressing, and there is no reliable cure (though some treatments help).

Overview

Hallucinogen persisting perception disorder (HPPD) is a condition in which someone re-experiences visual perceptual distortions — like those from a psychedelic trip — while sober, after the drug has fully left the body. Common symptoms include afterimages, trails behind moving objects, halos around lights, geometric patterns, flashes of color, altered size perception (objects seeming larger or smaller), and 'visual snow'. It is recognized in the DSM-5. Researchers describe two forms: Type 1, brief and occasional 'flashbacks', and Type 2, persistent changes to vision that wax and wane over months or years. It is most associated with LSD but has been linked to psilocybin, MDMA, mescaline, 2C-B, DMT, ketamine, and cannabis. Symptoms can appear from weeks to years after use, sometimes without any trigger.

Source: peer-reviewed literature (NIH/PMC); DSM-5; Wikipedia (CC-BY-SA)

Risks & harms

HPPD's risk profile is unusual and often misunderstood, so honest framing matters. First, it is not acutely dangerous — HPPD will not kill you or cause physical harm the way an overdose can; the disturbances are perceptual, not a sign of ongoing intoxication or brain damage. Second, genuine chronic (Type 2) HPPD is rare — estimated at roughly 1 in 50,000 hallucinogen users — although milder, transient flashback-type effects are reported more commonly. Third, and importantly, the real burden of HPPD is psychological: persistent visual changes can cause significant anxiety, distress, and functional impairment, and anxiety itself can worsen the perception of symptoms, creating a feedback loop. There is no established cure, and notably, antipsychotic medications often fail to help and can sometimes worsen it; case reports suggest lamotrigine, clonidine, and benzodiazepines may reduce symptoms for some people, and many milder cases fade over time. Risk factors are not fully understood, but pre-existing anxiety and heavy or high-dose hallucinogen use may contribute. Because HPPD can resemble other conditions (migraine aura, visual snow syndrome, or psychiatric illness), anyone with persistent visual disturbances should see a doctor to rule out other causes rather than self-diagnosing. If perceptual changes come with severe distress, thoughts of self-harm, or a break from reality, seek professional help promptly. This page has not yet been medically reviewed.

Source: peer-reviewed literature (NIH/PMC); Wikipedia (CC-BY-SA)

Images

Visual references coming soon.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

PubChem CID
N/A — no single PubChem compound (mixture/class/plant/concept)
IUPAC name
N/A — no single PubChem compound (mixture/class/plant/concept)
Molecular formula
N/A — no single PubChem compound (mixture/class/plant/concept)
SMILES
N/A — no single PubChem compound (mixture/class/plant/concept)
InChIKey
N/A — no single PubChem compound (mixture/class/plant/concept)
Synonyms / aliases
hallucinogen persisting perception disorder, visual snow

Composition

Composition
Unknown — pending review (no single compound; needs an epidemiology / composition source)

Physical / pill characteristics

Dosage form
Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
Route
Unknown — pending review
Shape
Unknown — pending review
Color
Unknown — pending review
Imprint
Unknown — pending review
Score
Unknown — pending review

Scheduling & legal status

US schedule
Unknown — pending review
International
See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA · retrieved 2026-06-18

Effects

Effects
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Risks

Risks
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Interactions

Interactions
Unknown — pending review

Sources

← Back to the drug index